Clalit 12-Year Data Find No Excess Cardiovascular Risk With Hormone Therapy in Women 45–59

A matched cohort of 52,330 women aged 45 to 59 found no excess risk of heart attack, stroke, blood clots, or death over 12 years — with no meaningful difference between oral and transdermal formulations.

A wide canopy shelters rows of small silhouettes from falling drops, representing a large cohort of women protected from cardiovascular harm over many years.

CLINICAL CATALYST · CARDIOVASCULAR STUDY DATA · NOVEMBER 15, 2026 · ISRAEL

Twelve years of follow-up data from Israel’s largest health maintenance organization have produced new observational evidence on the cardiovascular safety of menopausal hormone therapy (HT) — and the findings land at a moment when prescribing momentum is already accelerating. Researchers from Clalit Health Services, which provides care to about half of Israel’s population, presented results at the American Heart Association (AHA) Scientific Sessions in Chicago showing no excess risk of heart attack, stroke, venous thromboembolism (VTE), or death in women aged 45 to 59 who initiated HT, compared with matched controls who did not.

The study analyzed a retrospective, observational matched cohort of 52,330 women, half of whom initiated HT and half of whom did not, all free from atherosclerotic cardiovascular disease (ASCVD), VTE, and cancer at baseline, according to Healio’s reporting of the presentation. After a mean follow-up of 12 years, the ASCVD rate was 7.82 per 1,000 person-years in the HT group versus 7.99 in controls, yielding an adjusted hazard ratio (aHR) of 0.98 (95% confidence interval [CI], 0.93–1.04). The VTE rate was 0.56 per 1,000 person-years in both groups — 174 events in the HT group against 175 in controls — an aHR of 1.01 (95% CI, 0.82–1.24). Death before age 80 ran at 2.13 per 1,000 person-years in the HT group versus 2.10 in controls, aHR 1.03 (95% CI, 0.92–1.15). The composite of all three outcomes was 10.05 per 1,000 person-years in both groups, aHR 1.00 (95% CI, 0.96–1.06).

aHR 1.00

The composite of ASCVD, VTE, and death before age 80 yielded an adjusted hazard ratio of 1.00 (95% CI, 0.96–1.06) across 52,330 women over 12 years, per Healio’s reporting of the Clalit presentation.

Route of administration: the oral-transdermal question

The route-of-administration finding carries particular commercial weight. Other studies have reported an advantage for transdermal delivery over oral tablets. The Clalit data do not support that distinction. Results did not vary by type of HT or route of administration, according to the researchers. Ronen Arbel, PhD, Fellow of the European Society of Cardiology (FESC) and Fellow of the American Heart Association (FAHA), head of innovation and research at the Community Medical Services Division of Clalit Health Services in Tel Aviv, Israel, and an associate professor in the Maximizing Health Outcomes Research Lab at Sapir College in Sderot, Israel, told Healio: ‘The genuine surprise was venous thromboembolism: 174 events with HT vs. 175 without: no excess risk at all, and no meaningful difference between oral, transdermal and gel preparations. Other studies have reported an advantage for transdermal routes, and there is a plausible pathophysiologic explanation: avoidance of hepatic first pass. Our data suggest that oral tablets are equally safe in this population.’

For manufacturers of oral HT formulations, this finding could indicate a broadening prescribing base.

The regulatory backdrop: boxed-warning risk language narrowed, demand rising

The study’s timing is inseparable from its policy context. The FDA initiated removal of boxed warnings from HT products in November 2025, following a comprehensive review of the scientific literature, an expert panel convened in July 2025, and a public comment period, according to FDA announcements. The boxed warning for endometrial cancer remains on systemic estrogen-alone products. By February 2026, the agency had approved labeling changes for six products spanning all four categories of HT — systemic combination therapy (estrogen and progestogen), systemic estrogen-alone therapy, systemic progestogen-alone therapy, and topical vaginal estrogen therapy. The FDA’s updated prescribing information list names Prometrium, Divigel, Cenestin, Enjuvia, Minivelle, Vivelle, Vivelle-Dot, Estring, and Bijuva. At the FDA’s request, 29 drug companies submitted proposed labeling changes, the agency said in February 2026.

Arbel framed the study’s purpose explicitly in that context, telling Healio: ‘In November 2025, the FDA removed the black box warning from hormone replacement therapy products, and we have since seen a steep rise in the number of women starting hormone therapy (HT). Much of that momentum is driven by media coverage and social media rather than by clinical consultation. Because the original warning bundled cardiovascular disease together with breast cancer, dementia and endometrial cancer, its removal has been widely read as meaning that HT now carries no risk at all. Women are arriving at their physicians not to ask whether they should take HT, but to request it, and some say explicitly that they want it to lower their cardiovascular risk. Clinicians need real data to answer that question, in either direction.’

Reuters reported in April 2026 that the FDA’s HT push had strained estrogen patch supplies, with shortages potentially lasting years — a supply-side constraint that the oral-transdermal parity finding makes more operationally relevant. If oral formulations are clinically interchangeable on cardiovascular safety grounds, the supply pressure on transdermal products could be partially absorbed by redirecting patients to oral options, though that substitution would require prescriber and patient acceptance that the Clalit data alone cannot guarantee.

Arbel told Healio the team ‘held to a strict target-trial design’ because the randomized trials that shaped practice ‘used higher-dose formulations that are largely obsolete, in women who began treatment many years after menopause.’ The Women’s Health Initiative (WHI) study cited by the FDA enrolled women who averaged 63 years old — more than a decade past the average age of menopause — and used a hormone formulation no longer in common use, according to the FDA. The Clalit cohort, by contrast, enrolled women aged 45 to 59 initiating contemporary formulations, matched on age, body mass index (BMI), blood pressure, lipids, diabetes, smoking status, and socioeconomic status. Arbel told Healio the findings ‘help settle the long shadow cast by the Women’s Health Initiative, which led a generation of physicians and patients to abandon HT altogether,’ and are ‘consistent with [the American College of Obstetricians and Gynecologists’] recommendation to start HT within 10 years of menopause onset and before age 60.’

The study carries limitations that Arbel stated directly. As an observational study, it cannot establish causation. Factors not captured in the health records — physical activity, diet, and severity of menopausal symptoms — may still differ between groups. Women were classified by their first formulation without accounting for later changes in type or route. And the population studied was explicitly bounded: women with established cardiovascular disease, prior thromboembolism, or cancer were excluded, as were women initiating treatment well after menopause. Arbel was explicit that ‘these results should not be extrapolated beyond the population we studied.’ He added that ‘HT should be prescribed to treat menopausal symptoms — not as cardiovascular prevention.’ The findings are also preliminary: abstracts presented at AHA Scientific Sessions are not peer-reviewed, and the results are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.

Maven Clinic, a virtual provider for women’s and family health, announced a direct-to-consumer (DTC) hormone therapy offering in March 2026 and launched it in May 2026 at a one-time fee of $150 including two virtual visits, plus medication costs, according to Fierce Healthcare — a commercial signal that demand-side infrastructure is already forming around the post-warning-removal environment, independent of the Clalit data.

What to Watch

  1. Peer-reviewed publication of the Clalit cohort manuscript, which will subject the methodology and matched-cohort design to formal scientific scrutiny and may influence clinical guideline updates
  2. Whether the FDA’s ongoing labeling process with the 29 companies that submitted proposed changes produces further approved label revisions, and whether those revisions address route-of-administration language specifically
  3. Supply-chain resolution for estrogen patches, which Reuters reported in April 2026 could face shortages lasting years — and whether oral formulation uptake accelerates as a practical substitute
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Step 1 of 2 · Free. Work email for instant access. Unsubscribe anytime. By subscribing you agree to receive The HealthSignals Brief by email and accept our Privacy Policy.

The deeper tension in the Clalit data is between what they confirm and what they cannot extend. They add contemporary cardiovascular safety evidence for HT in the 45-to-59 age window — but they are also a single observational study, presented before peer review, drawn from one national health system. The clinical guidance that will follow the FDA’s labeling action will need to hold both of those facts simultaneously.

Clalit 12-Year Hormone Therapy Safety Outcomes · N = 52,330 women aged 45–59

Outcome Hormone Therapy Group Control Group Adjusted Hazard Ratio (95% CI)
Atherosclerotic cardiovascular disease (ASCVD), per 1,000 person-years 7.82 7.99 0.98 (0.93–1.04)
Venous thromboembolism (VTE), per 1,000 person-years 0.56 0.56 1.01 (0.82–1.24)
Death before age 80, per 1,000 person-years 2.13 2.10 1.03 (0.92–1.15)
Composite outcome (ASCVD, VTE, or death before age 80), per 1,000 person-years 10.05 10.05 1.00 (0.96–1.06)

Source: Healio, reporting Clalit Health Services AHA presentation

Why this is relevant

Patients

Women aged 45 to 59 initiating contemporary menopausal hormone therapy showed no excess risk of atherosclerotic cardiovascular disease (ASCVD), venous thromboembolism (VTE), or death before age 80 over 12 years in the Clalit cohort. The findings may reassure patients and clinicians, though the study excluded women with established cardiovascular disease or prior thromboembolism, limiting extrapolation to higher-risk populations.

Industry

Oral hormone therapy formulations showed no difference in cardiovascular outcomes compared with transdermal and gel preparations in the Clalit data, which could indicate a broader prescribing base for oral products. Manufacturers of oral HT may benefit if route-of-administration guidance is revised, though any formulary or guideline change would follow peer review of the full manuscript and individual payer review cycles.

Payers

Formulary structures may face reassessment if the oral-transdermal parity finding is confirmed in peer-reviewed publication. Reuters reported in April 2026 that estrogen patch shortages could last years, adding operational pressure to coverage decisions for HT formulations.

Regulators

The Clalit cohort data appear consistent with the FDA’s November 2025 decision to initiate removal of boxed warnings from HT products, according to Arbel. The FDA’s labeling recommends starting systemic HT within 10 years of menopause onset or before age 60. At the FDA’s request, 29 drug companies submitted proposed labeling changes, per the agency’s February 2026 announcement.

Sources: Healio: Contemporary hormone therapy does not worsen cardiovascular risk · FDA: FDA Approves Labeling Changes to Menopausal Hormone Therapy Products · FDA: HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy · Reuters: Patients scramble to find estrogen patches as shortage worsens after US FDA champions use · Fierce Healthcare: Maven Clinic launches DTC vertical focused on GLP-1s, hormone care · FDA: Menopausal Hormone Therapies with Updated Prescribing Information · Israel State Comptroller: Clalit Health Services finances (2024)

THE HEALTHSIGNALS BRIEF

A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.

Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.

Your subscription could not be validated.
You have successfully subscribed.

Comments

Related